Journal of Clinical and Aesthetic Dermatology

Updates on Psoriasis & Cutaneou Oncology

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/882293

Contents of this Issue

Navigation

Page 7 of 43

S8 P r o c e e D i n G s JCAD jOUrnAl Of ClInICAl And AEsthEtIC dErMAtOlOgy september 2017 • volume 10 • number 9 • supplement a M E s s A g E f r o m t h e Dear colleagues: this year's MauiDerm 2017 supplement features several topics presented by our faculty that are relevant to your daily clinical practice. Given the rapid changes in the therapeutic landscape of dermatology, it is vital to stay abreast of new and novel therapies that can be both life changing and lifesaving to our patients. the following pages contain engaging scientifc and clinical discussions of the latest advances in both psoriasis and cutaneous oncology, as well as case studies in challenging pediatric diseases. i hope that you fnd the content both engaging and educational. We thank the educational sponsors of the MauiDerm meeting and this supplement for their commitment to dermatology and dermatology education. With aloha, george Martin, Md MauiDerm 2017 Program Director; Guest Editor, the Journal of Clinical and Aesthetic Dermatology by jo Ann leQuang Ms. LeQuang is a medical writer with LeQ Medical in Angleton, Texas. J Clin Aesthet Dermatol. 2017;10(9 suppl):s8–s41 t PsOrIAsIs UPdAtE 2017 tHe unveil stuDy, a randomized, placebo- controlled, double-blind, multicenter, Phase 4 study ( nct02425826) of the eecacy and safety of apremilast for the treatment of moderate plaque psoriasis was recently published. 1 apremilast is a novel immunomodulatory medication approved for treatment of both psoriasis and psoriatic arthritis. it inhibits the activity of phosphodiesterase 4 (PDe4), which is active in immune system cells as well as in keratinocytes. reducing PDe4 may decrease production of proingammatory cytokines. to enroll in the study, adults (≥18 years) had to have chronic plaque psoriasis for at least six months prior to screening. chronic plaque psoriasis was defned as a body surface area (Bsa) of 5 to 10 percent and a score on the static Physician's Global assessment (sPGa) of 3 on a scale of 0 to 5. the product of these two scores accordingly could range from 15 to 30 at screening and baseline. Patients were included when they had not previously been exposed to conventional systemic or biologic therapy for psoriatic arthritis, psoriasis, or any indication which might impact psoriasis assessment. the main exclusionary criterion was any ingammatory and/or dermatologic condition other than plaque psoriasis (including other forms of psoriasis). in the unveil study, patients were randomized in a 2:1 scheme to receive apremilast or placebo for the frst 16 weeks; at Week 16, placebo patients were switched to apremilast. all patients then continued on apremilast in open-label treatment until the end of the study (Week 52). the primary eecacy endpoint was the mean percentage change from baseline at Week 16 in sPGa x Bsa. the sPGa score was calculated for all plaques in all involved areas, erythema severity, scaling, and plaque elevation; these scores were then averaged and rounded to the nearest whole number. the secondary eecacy endpoints were the mean percentage change from baseline in the Psoriasis area and severity index (Pasi) score, the percentage of patients PsOrIAsIs Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting george Martin, Md D ermatology Associates, Kihei, Maui, Hawaii Guest editor and MauiDerm Program Director

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Updates on Psoriasis & Cutaneou Oncology